Specialty Firms Shoot Down Big Money Bids
CV Therapeutics and Genetech rejected offers from big-name suitors. Are they playing hard to get or are they just not that into them?
Pfizer Pulls Two Late-stage Drugs from Development
A sign of the times or a rash decision? In an effort to curb unnecessary costs, Pfizer kills development of two late-stage products rather than sink more money into them.
